MetLife Investment Management’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-17,001
| Closed | -$170K | – | 2885 |
|
|
2025
Q2 | $170K | Buy |
17,001
+2,958
| +21% | +$23.8K | ﹤0.01% | 2276 |
|
|
2025
Q1 | $83.8K | Hold |
14,043
| – | – | ﹤0.01% | 2598 |
|
|
2024
Q4 | $108K | Hold |
14,043
| – | – | ﹤0.01% | 2585 |
|
|
2024
Q3 | $143K | Hold |
14,043
| – | – | ﹤0.01% | 2460 |
|
|
2024
Q2 | $208K | Buy |
14,043
+1,365
| +11% | +$19.6K | ﹤0.01% | 2216 |
|
|
2024
Q1 | $173K | Hold |
12,678
| – | – | ﹤0.01% | 2272 |
|
|
2023
Q4 | $139K | Hold |
12,678
| – | – | ﹤0.01% | 2437 |
|
|
2023
Q3 | $139K | Hold |
12,678
| – | – | ﹤0.01% | 2408 |
|
|
2023
Q2 | $168K | Hold |
12,678
| – | – | ﹤0.01% | 2385 |
|
|
2023
Q1 | $173K | Hold |
12,678
| – | – | ﹤0.01% | 2305 |
|
|
2022
Q4 | $248K | Hold |
12,678
| – | – | ﹤0.01% | 2114 |
|
|
2022
Q3 | $242K | Hold |
12,678
| – | – | ﹤0.01% | 2159 |
|
|
2022
Q2 | $261K | Hold |
12,678
| – | – | ﹤0.01% | 2123 |
|
|
2022
Q1 | $408K | Buy |
12,678
+4,679
| +58% | +$170K | ﹤0.01% | 1898 |
|
|
2021
Q4 | $372K | Hold |
7,999
| – | – | ﹤0.01% | 1664 |
|
|
2021
Q3 | $216K | Hold |
7,999
| – | – | ﹤0.01% | 2041 |
|
|
2021
Q2 | $205K | Hold |
7,999
| – | – | ﹤0.01% | 2162 |
|
|
2021
Q1 | $273K | Buy |
7,999
+3,036
| +61% | +$110K | ﹤0.01% | 1873 |
|
|
2020
Q4 | $168K | Hold |
4,963
| – | – | ﹤0.01% | 2075 |
|
|
2020
Q3 | $122K | Buy |
+4,963
| New | +$133K | ﹤0.01% | 2118 |
|
Other funds holding ITOS
MetLife Investment Management's ITOS Position: Q3 2025 in Review
MetLife Investment Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 17,001 shares — an estimated $170K sold.
MetLife Investment Management first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $408K in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- MetLife Investment Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- MetLife Investment Management sold 17,001 iTeos Therapeutics shares in Q3 2025, an estimated $170K.
- MetLife Investment Management first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- MetLife Investment Management's iTeos Therapeutics position peaked at $408K in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.